YARDSTICK Take the audit Join the Waitlist

Yardstick Research tear-sheet / pharma & life sciences CRM cohort

Methodology · how we score · rubric weights in plain sight · vendors received this sheet seven days before publication and could flag factual errors, never rankings

Komodo Health

Identity

Total score: 77.5 / 100

Headline numbers

Metric Value Evidence
Free tier? No - enterprise sales-led only [VENDOR-CLAIMED - https://www.komodohealth.com/]
Pricing Not published; enterprise contract required [UNKNOWN]
Customer count Not publicly disclosed [UNKNOWN]
Healthcare Map records 1 trillion+ linked records; 330M+ patient journeys, refreshed daily [VENDOR-CLAIMED - https://www.komodohealth.com/]
Validated analyses 1M+ validated healthcare analyses [VENDOR-CLAIMED - https://www.komodohealth.com/]
CMS Qualified Entity Yes - CMS QE certification confirms access to Medicare/Medicaid data for comparative effectiveness research [VENDOR-CLAIMED - https://www.komodohealth.com/]
Funding (Series F) $200M raised September 2023; led by Coatue [THIRD-PARTY - https://www.linkedin.com/company/komodo-health/]
Headcount ~757 (LinkedIn, as of research date) [THIRD-PARTY - https://www.linkedin.com/company/komodo-health/]
Compliance HIPAA compliance inferred from healthcare data operations; SOC 2 / ISO 27001 / 21 CFR Part 11 not confirmed on public trust page [UNKNOWN - trust/compliance page returned 404 as of research date]

Dimension scores

Dimension Score Weight Weighted Evidence
AI capability depth 4/4 15 15.0 [VENDOR-CLAIMED] Marmot is Komodo's healthcare-native AI platform, delivering "reproducible, traceable, and governed AI insights you can defend and show the work." Key capabilities: cohort identification, methodology versioning, audit-ready analysis outputs, and validated analyses against the 1M+ benchmark. Blog posts (ISPOR 2026, "Why Foundational LLMs Fail on Healthcare Data," "Architecting Trust: Building the Framework for Trusted AI in Healthcare") show a mature AI team publishing on governance and validation - differentiated from generic LLM overlays. CMS QE certification further validates the underlying data quality. - https://www.komodohealth.com/, https://www.komodohealth.com/blog/
Workflow integration depth 3/4 20 15.0 [VENDOR-CLAIMED + UNKNOWN] Komodo Home provides a unified UX for commercial, HEOR, and medical affairs workflows. Integration with Veeva Vault CRM and Salesforce Health Cloud (listed in D1 integrates_with) enables commercial teams to bring Komodo's prescribing and patient journey data into their CRM workflows. Gap: specific API documentation, bidirectional data exchange depth, and CRM connector certification details are not available on a public surface. CMS QE certification enables access to regulatory-quality claims data for reporting workflows. - https://www.komodohealth.com/
Vertical specialization 4/4 20 20.0 [VENDOR-CLAIMED] Healthcare-exclusive platform; no horizontal market ambitions. The Healthcare Map is specifically built for US healthcare data (Medicare/Medicaid via CMS QE, commercial claims, prescription data, lab data, specialty pharmacy data). Commercial, HEOR/RWE, medical affairs, and clinical development all served. GeneDx partnership (January 2026) extends the platform into rare disease genomics. Pharma Exec, Technology Networks, Healthcare Brew, and Medscape have all published Komodo-powered research analyses. - https://www.komodohealth.com/, https://www.komodohealth.com/news
Implementation + time-to-value 3/4 5 3.75 [VENDOR-CLAIMED] Komodo Home provides a unified, query-first UX designed to reduce the time from business question to data answer for commercial analytics teams. The 1M+ validated analyses library means common commercial analytics questions (market share, patient journey, HCP prescribing patterns) have pre-built methodologies rather than requiring ground-up development. Gaps: initial data integration and credentialing setup is multi-week at minimum; rare disease or custom cohort work requires analytical services investment. - https://www.komodohealth.com/
Data + compliance posture (HIPAA/21CFR11) 3/4 20 15.0 [VENDOR-CLAIMED partial + UNKNOWN] CMS QE certification is the strongest verifiable compliance signal - it requires CMS oversight of data governance practices for Medicare/Medicaid claims. Patient data is de-identified (patient journeys, not identifiable records). HIPAA compliance is operational necessity for Komodo's data business but is not confirmed via a public BAA or trust center page (trust/compliance pages returned 404 at research date). SOC 2 Type II, ISO 27001, and 21 CFR Part 11 are not confirmed on any public surface. 21 CFR Part 11 is less directly applicable to a commercial analytics/RWD platform than to content management or clinical trial platforms, but pharma buyers with enterprise security review processes will need to request documentation directly. - https://www.komodohealth.com/
Pricing + scalability 2/4 5 2.5 [UNKNOWN] No public pricing page. Enterprise contract required. The combination of data platform access, Marmot AI workflows, and analytical services creates a multi-line invoice that is not transparent from a public surface. Series F funding ($200M, 2023) indicates institutional confidence in revenue scalability. - https://www.komodohealth.com/
Vendor strength + named-customer evidence 3/4 15 11.25 [VENDOR-CLAIMED + THIRD-PARTY] $620M+ in funding; $200M Series F led by Coatue (2023) validates institutional confidence. CMS QE certification is a meaningful regulatory credential. Peer-reviewed research published via Komodo data (ISPOR, Technology Networks, Medscape). GeneDx partnership demonstrates named-partner relationships in adjacent life sciences categories. Gaps: named pharma customer case studies are not prominently published (testimonial from "VP of Sales, Top 20 Pharma" is anonymous); no KLAS or Gartner peer review rating surfaced. Top-20 pharma customer presence is implied by headcount and funding trajectory but not publicly confirmed. - https://www.komodohealth.com/, https://www.komodohealth.com/news
Total 100 82.5 − 5 (soft) = 77.5

Pricing detail

Komodo Health does not publish pricing on any public surface. [UNKNOWN]

Key structural notes: - Platform access fee: Enterprise license for Healthcare Map access, Komodo Home UX, and Marmot AI workflows. Not published. - Analytical services layer: Custom cohort builds, rare disease datasets (e.g., GeneDx partnership), and methodology development are delivered by Komodo's analytical services team and priced separately. - CMS QE access: The CMS Qualified Entity certification enables access to regulated Medicare/Medicaid data products that are subject to CMS-mandated pricing and use restrictions; standard commercial data access is separate. - Series F ($200M, 2023) context: Capital allocation suggests continued investment in platform development rather than near-term profitability optimization; pricing is competitive on enterprise data platform benchmarks.

Integrations

Source: D1 integrates_with column; https://www.komodohealth.com/

The integrates_with column for this vendor in D1 lists: veeva-vault-crm, salesforce-health-cloud.

Editorial assessment

Komodo Health occupies a distinct and defensible position in the pharma CRM and commercial intelligence stack: it is not a CRM or an engagement orchestration tool, it is the data foundation that makes CRM-based HCP targeting smarter. The Healthcare Map's 330M+ patient journeys (refreshed daily) and the CMS Qualified Entity certification together represent a real-world data asset that is difficult to replicate - the QE certification in particular requires CMS oversight of data governance practices and enables access to Medicare/Medicaid claims data for comparative effectiveness reporting that most competitors cannot access at the same compliance level. Marmot's emphasis on reproducible, auditable, governed AI outputs is the right posture for a pharma analytics workflow where results feed into regulatory submissions or payer negotiations.

The compliance documentation gap is the primary procurement risk. Komodo operates inside top-20 pharma clients with rigorous vendor qualification requirements - the existence of a robust compliance posture is operationally implied - but the trust/compliance page returned 404 at research date, and no SOC 2 Type II, ISO 27001, or 21 CFR Part 11 confirmation surfaces on any public page. Pharma buyers with annual vendor security reviews will need to request this documentation directly through procurement rather than verifying it from a public trust center. This is not a dealbreaker for a platform whose primary use case (commercial analytics on de-identified real-world data) has lower 21 CFR Part 11 exposure than a content management or electronic records platform, but it adds procurement friction.

The named-customer evidence gap is the other notable limitation. The testimonial on the homepage is from "VP of Sales, Top 20 Pharma" - anonymous. The GeneDx partnership and ISPOR research publications are credible signals, but named pharma commercial use-case case studies (equivalent to the Abridge-KUMC level of disclosure) are not prominent on the Komodo website. Buyers in competitive evaluations who need to present named customer evidence to internal stakeholders will need to get this from Komodo directly.

For buyers with mature commercial analytics or HEOR functions who need a real-world data platform with governed AI on top, Komodo is the strongest choice in the cohort. For buyers who need field force orchestration or CRM-native NBA recommendations, ZAIDYN is better positioned.

Best for

Right-of-reply

Komodo Health received this tear-sheet seven calendar days before publication of the Yardstick Research 2026 Yardstick Report, including all measured numbers, sample outputs, and editorial assessment. Komodo Health was given the opportunity to flag factual errors - incorrect pricing, misquoted feature availability, outdated screenshots, factual misstatement in the editorial assessment. Komodo Health was not given the opportunity to request a score revision, dispute the rubric or its weights, withdraw from inclusion, negotiate ranking placement, or suggest changes to the editorial assessment beyond factual correction. Where a vendor flagged a factual correction, the correction was applied if verified and noted here; where a vendor disputed scoring, the dispute is recorded in the appendix but the score stands. Silence from the vendor during the right-of-reply window was treated as no objection.

Right-of-reply gaps

Specific [UNKNOWN] items surfaced in the dossier and explicitly raised with the vendor in right-of-reply:

  1. SOC 2 Type II. No public SOC 2 report or trust center page was accessible on komodohealth.com as of research date (trust/compliance pages returned 404). Does Komodo Health hold SOC 2 Type II? Where can procurement teams access the report?
  2. ISO 27001. Is ISO 27001 held? If so, what is the certification scope and audit date?
  3. 21 CFR Part 11. Komodo's primary use cases are commercial analytics and RWE rather than FDA electronic records submissions, but pharma buyers may require a 21 CFR Part 11 compliance statement for vendor qualification. Is one available?
  4. HIPAA BAA. Does Komodo execute BAAs with pharma commercial clients? The Healthcare Map uses de-identified data; under what conditions is a BAA required?
  5. Veeva / Salesforce integration depth. For the listed CRM integrations: is this a data feed (Komodo prescribing data delivered via API into CRM territory management), a native UI integration, or an analyst-facing analytics connector? What is the typical implementation time for a CRM data integration?
  6. Named customer case studies. Are published case studies with quantified outcomes available for procurement review? The homepage testimonial is anonymous ("VP of Sales, Top 20 Pharma").
  7. Series F total and total funding. The LinkedIn profile references $200M in January 2023 and Coatue as an investor. What is the confirmed total funding raised across all rounds?
  8. Marmot model provenance. What LLM or ML infrastructure underpins Marmot? Proprietary models, fine-tuned foundation models, or third-party API calls?

Sources

Komodo Health first-party: - https://www.komodohealth.com/ - https://www.komodohealth.com/news - https://www.komodohealth.com/blog/ - https://www.komodohealth.com/solutions/life-sciences/

Third-party: - https://www.linkedin.com/company/komodo-health/

Note on research limitations: komodohealth.com/trust/, /about/, and several subpages returned 404 as of research date. Compliance certifications, named customer case studies, and funding totals were not confirmable from a single primary source. Buyers should request the SOC 2 Type II report, ISO 27001 certificate, and named pharma customer references directly from Komodo Health's sales team.